The 6th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19th at 9pm ET
BALTIMORE, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics is pleased to announce that its strategic advisor and developer of GCANRx’s licensed cannabinoid therapeutic, Dr. Adi Aran, M.D., will be interviewed as a world-renowned thought leader and pioneer in cannabis research on CNN’s Award-winning Series airing Sunday, December 19th at 9 pm ET.
In the original Award-winning documentary CNN chief medical correspondent Dr. Sanjay Gupta sets out around the globe to investigate the medical benefits of medical marijuana. WEED, which premiered in 2015, highlights the remarkable benefits of CBD and the changing laws granting parents and doctors the ability to use CBD in treating children. In this documentary, Gupta follows several families who have seen the miraculous benefits of the plant on their children struggling with autism. Dr. Aran is regarded as a world-renowned expert on autism and cannabinoid research and is credited with conducting pioneering clinical studies on the use of cannabinoid therapeutics in autism.
CNN Special Report WEED 6: Cannabis and Autism will stream live for cable subscribers via CNNgo (CNN.com/go and via CNNgo apps for Apple TV, Roku, Amazon Fire, Chromecast, Samsung Smart TV and Android TV) and on the CNN mobile apps for iOS and Android. The special will be available on demand beginning Sunday, December 19th via cable/satellite systems, CNNgo platforms and CNN mobile apps.
For more information about the special visit https://cnnpressroom.blogs.cnn.com/2021/12/02/cnn-special-report-weed-6-cannabis-and-autism/
About Dr. Adi Aran, M.D.
Dr. Aran is a physician, scientist, respected key opinion leader and inventor of the cannabinoid neuropsychiatric therapeutic that the Company has licensed from Shaare Zedek Scientific Ltd. He is also the Director of Pediatric Neurology at Shaare Zedek Medical Center in Jerusalem. Dr. Aran is well known for his pioneering study on cannabinoids in autistic children. He specializes in the diagnosis and treatment of Autism Spectrum Disorder (ASD) and related genetic disorders. His research is focused on the endocannabinoid system involvement in ASD and related genetic disorders and the evaluation of new therapies for the treatment of these disorders. Dr. Aran serves as a member of the International Society for Autism Research. He completed his medical studies at the Hebrew University and continued his training as Postdoctoral research fellow in Stanford, CA. Dr. Aran is regarded as a pioneer in the research of medical cannabis in Autism, a subject that is currently receiving public attention worldwide.
ENDS
For GCANRx Investor Relations inquiries visit www.gcanrx.com, or contact info@gcanrx.com. To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.
About Greater Cannabis Company: The Greater Cannabis Company (OTCQB: GCAN), (“GCANRx” or the “Company”) is a fully reporting publicly traded biopharmaceutical company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop innovative cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. GCANRx’s mission is to bring its products to the global market for the benefit of patients seeking better solutions for their unmet medical needs.
Disclaimer: Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not strictly historical are “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the uncertainty regarding viability and market acceptance of the Company’s products and services, the ability to complete development plans in a timely manner, changes in relationships with third parties, product mix sold by the Company and other factors described in the Company’s most recent periodic filings with the Securities and Exchange Commission, including its 2020 Annual Report on Form 10-K and quarterly reports on Form 10-Q.
Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: The Greater Cannabis Company, Inc.
443-738-4051
info@gcanrx.com
www.gcanrx.com
Attachment
